Patents by Inventor Wai C. Wong
Wai C. Wong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7273880Abstract: This invention is directed to bicyclic and tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. The invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.Type: GrantFiled: January 20, 2005Date of Patent: September 25, 2007Assignees: H. Lunbeck A/S, Novartis AGInventors: Mohammad R. Marzabadi, Wai C. Wong, Stewart A. Noble, Yasuchika Yamaguchi
-
Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
Patent number: 7071207Abstract: This invention relates to 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.Type: GrantFiled: September 24, 2002Date of Patent: July 4, 2006Assignee: Bayer Pharmaceuticals CorporationInventors: Roger A. Smith, Stephen J. O'Connor, Wai C. Wong, Soongyu Choi, Harold C. Kluender, Jianmei Fan, Zhonghua Zhang, Rico C. Lavoie, Brent L. Podlogar -
Patent number: 6989379Abstract: This invention is directed to triazine derivatives, bicyclic compounds and tricyclic compounds which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.Type: GrantFiled: April 21, 2000Date of Patent: January 24, 2006Assignee: H. Lundbick A/SInventors: Mohammad R. Marzabadi, Wai C. Wong, Stewart A. Noble, Manesh N. Desai
-
Patent number: 6960601Abstract: This invention relates to substituted imidazole derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.Type: GrantFiled: September 24, 2002Date of Patent: November 1, 2005Assignee: Bayer Pharmaceuticals CorporationInventors: Roger A. Smith, Stephen J. O'Connor, Stephan-Nicholas Wirtz, Wai C. Wong, Soongyu Choi, Harold C. E. Kluender, Ning Su, Gan Wang, Furahi Achebe, Shihong Ying
-
Publication number: 20040236110Abstract: The invention provides novel substituted 3-pyridyl indoles and indazoles and pharmaceutical compositions thereof. The invention also provides methods of use of substituted 3-pyridyl indoles and indazoles and pharmaceutical compositions thereof as inhibitors of lyases, e.g., the 17&agr;-hydroxylase-C17,20-lyase enzyme. The invention further provides methods for the treatment of cancer in a subject, comprising administering a substituted 3-pyridyl indoles and indazoles or a pharmaceutical composition comprising a substituted 3-pyridyl indoles and indazoles to a subject. The cancer can be, e.g., prostate cancer or breast cancer.Type: ApplicationFiled: March 26, 2004Publication date: November 25, 2004Inventors: Gaetan H Ladouceur, Michael Burke, Wai C Wong, Donald E Bierer
-
Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
Publication number: 20040224970Abstract: This invention relates to 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.Type: ApplicationFiled: February 27, 2004Publication date: November 11, 2004Inventors: Roger A Smith, Stephen J. O'Connor, Wai C. Wong, Soongyu Choi, Harold C.E. Kluender, Jianmei Fan, Zhonghua Zhang, Rico C. Lavoie, Brent L. Podlogar -
Patent number: 6777426Abstract: This invention is directed to novel imidazole and imidazoline derivatives which are selective agonists for cloned human &agr;2 adrenergic receptors. This invention is also related to the use of these compounds for the treatment of any disease where modulation of the &agr;2 receptors may be useful. The invention further provides for a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: August 20, 2001Date of Patent: August 17, 2004Assignee: Synaptic Pharmaceutical CorporationInventors: Wai C. Wong, Yoon T. Jeon, T. G. Murali Dhar, Charles Gluchowski
-
Patent number: 6727257Abstract: This invention is directed to dihydropyrimidine compounds of the following formula: wherein A is which are selective antagonists for human &agr;1C receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where antagonism of the &agr;1C receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: December 5, 2000Date of Patent: April 27, 2004Assignee: Synaptic Pharmaceutical CorporationInventors: Dhanapalan Nagarathnam, George Chiu, T. G. Murali Dhar, Wai C. Wong, Mohammad R. Marzabadi, Charles Gluchowski, Bharat Lagu, Shou Wu Miao
-
Publication number: 20040063691Abstract: This invention relates to substituted imidazole derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.Type: ApplicationFiled: September 24, 2002Publication date: April 1, 2004Inventors: Roger A. Smith, Stephen J. O'Connor, Stephan-Nicholas Wirtz, Wai C. Wong, Soongyu Choi, Harold C.E. Kluender, Ning Su, Gan Wang, Furahi Achebe, Shihong Ying
-
Patent number: 6620815Abstract: This invention is directed to oxazolidinone compounds which are selective antagonists for human &agr;1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the &agr;1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: August 10, 2000Date of Patent: September 16, 2003Assignee: Synaptic Pharmaceutical CorporationInventors: Bharat Lagu, T. G. Murali Dhar, Dhanapalan Nagarathnam, Yoon T. Jeon, Mohammad R. Marzabadi, Wai C. Wong, Charles Gluchowski
-
Patent number: 6608086Abstract: This invention provides dihydropyridines useful for treatment of prostatic hyperplasia, inhibition of cholesterol synthesis, and/or reduction of intraocular pressure.Type: GrantFiled: October 5, 2001Date of Patent: August 19, 2003Assignee: Synaptic Pharmaceutical CorporationInventors: Charles Gluchowski, John M. Wetzel, George Chiu, Mohammed R. Marzabadi, Wai C. Wong, Dhanapalan Nagarathnam
-
Publication number: 20020193599Abstract: The invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure: 1Type: ApplicationFiled: October 5, 2001Publication date: December 19, 2002Applicant: Synaptic Pharmaceutical CorporationInventors: Charles Gluchowski, John M. Wetzel, George Chiu, Mohammed R. Marzabadi, Wai C. Wong, Dhanapalan Nagarathnam
-
Publication number: 20020019390Abstract: This invention is directed to novel imidazole and imidazoline derivatives which are selective agonists for cloned human &agr;2 adrenergic receptors. This invention is also related to the use of these compounds for the treatment of any disease where modulation of the &agr;2 receptors may be useful. The invention further provides for a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: ApplicationFiled: August 20, 2001Publication date: February 14, 2002Applicant: Synaptic Pharmaceutical CorporationInventors: Wai C. Wong, Yoon T. Jeon, T.G. Murali Dhar, Charles Gluchowski
-
Publication number: 20020010186Abstract: This invention is directed to dihydropyrimidine compounds which are selective antagonists for human &agr;1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the &agr;1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: ApplicationFiled: May 15, 2001Publication date: January 24, 2002Applicant: Synaptic Pharmaceutical CorporationInventors: Wai C. Wong, Bharat Lagu, Dhanapalan Nagarathnam, Mohammad R. Marzabadi, Charles Gluchowski
-
Patent number: 6310076Abstract: The invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure: wherein Y is —(CH2)n—, where n is 1, 2, 3, 4 or 5; —(CH2)h—O—(CH2)k—, where h and k are independently the same or different and are 2, 3 or 4; —(CH2)h—CH═CH—(CH2)k—; or —(CH2)h—C≡C—(CH2)k—, where h and k are independently the same or different and are 1, 2, 3 or 4; wherein Z is O, NH, or CH2; wherein R1 is a linear or branched chain alkyl, alkoxyalkyl or arylalkyl group; wherein R2 and R4 are independently the same or different and are H, or it linear or branched chain alkyl group; wherein R3 is H, a linear or branched chain alkyl, alkoxy, alkoxyalkyl or acyl group; and wherein R5 and R6 are independently the same or different and are H, OH, Cl, Br, F, NO2, CN, CF3, or NH2, or a linear or branched chType: GrantFiled: June 7, 2000Date of Patent: October 30, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Charles Gluchowski, John M. Wetzel, George Chiu, Mohammed R. Marzabadi, Wai C. Wong, Dhanapalan Nagarathnam
-
Patent number: 6294566Abstract: This invention is directed to novel imidazole and imidazoline derivatives which are selective agonists for cloned human &agr;2 adrenergic receptors. This invention is also related to the use of these compounds for the treatment of any disease where modulation of the &agr;2 receptors may be useful. The invention further provides for a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: September 20, 1999Date of Patent: September 25, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Wai C. Wong, Yoon T. Jeon, Charles Gluchowski
-
Patent number: 6268369Abstract: This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human &agr;1C receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where antagonism of the &agr;1C receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: May 16, 1997Date of Patent: July 31, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Dhanapalan Nagarathnam, George Chiu, T. G. Murali Dhar, Wai C. Wong, Mohammad R. Marzabadi, Charles Gluchowski, Bharat Lagu, Shou Wu Miao
-
Patent number: 6248747Abstract: This invention is directed to the use of dihydropyrimidine compounds, which are selective antagonists for cloned human &agr;1C receptors, for the treatment of benign prostatic hyperplasia and other diseases where antagonism of the human &agr;1C receptor is useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-identified compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: April 14, 1999Date of Patent: June 19, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Dhanapalan Nagarathnam, George Chiu, T. G. Murali Dhar, Wai C. Wong, Mohammad R. Marzabadi, Charles Gluchowski
-
Patent number: 6245773Abstract: This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human &agr;1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where antagonism of the &agr;1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: May 16, 1997Date of Patent: June 12, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Wai C. Wong, Bharat Lagu, Dhanapalan Nagarathnam, Mohammad R. Marzabadi, Charles Gluchowski
-
Patent number: 6228861Abstract: This invention is directed to dihydropyrimidine compounds which are selective antagonists for human &agr;1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the &agr;1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: November 10, 1998Date of Patent: May 8, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Dhanapalan Nagarathnam, Wai C. Wong, Shou Wu Miao, Charles Gluchowski, Michael A. Patane